Nephrol Dial Transplant (2000) 15: 964-969
© 2000 European Renal Association-European Dialysis and Transplant Association
Capillary/myocyte mismatch in the heart in renal failure—a role for erythropoietin?
1 Department of Pathology, University of Heidelberg, Heidelberg, 2 Department of Pathology, University of Erlangen-Nürnberg, Erlangen, 3 Department of Pathology, Darmstadt, Darmstadt, 4 Department of Nephrology, Internal Medicine, University of Heidelberg, Heidelberg and 5 Department of Physiology I, University of Regensburg, Regensburg, Germany
Background. Chronic renal failure is characterized by remodeling of the heart with left ventricular hypertrophy (increasing oxygen demand) and capillary deficit leading to capillary/myocyte mismatch (decreasing oxygen supply). Erythropoietin (Epo) has known angiogenic properties causing endothelial cell activation, migration and sprouting, mediated at least in part via the JAK/STAT (Janus kinase/signal transducers and activators of transcription) pathway. In uraemic cardiac hypertrophy the presence of diminished capillary supply implies that capillary growth does not keep pace with development of hypertrophy. To investigate whether this was due to a deficit of the angiogenic hormone Epo we examined whether Epo levels are altered and whether an increase in haematocrit by administration of rhEpo influences capillary supply, i.e. capillary/myocyte mismatch in experimental renal failure.
Method. Male Spraque–Dawley rats were either subjected to partial renal ablation or sham operation. Only modest amounts of renal tissue were removed so that the rats were not anemic. Subgroups of rats received either human (rh)Epo alone or in combination with unspecific antihypertensive treatment (dihydralazine plus furosemide) in order to control the Epo induced rise in blood pressure. Capillary supply was measured stereologically as capillary length per volume myocardium using the orientator method.
Results. Capillary length density was reduced by approximately 25% after partial renal ablation (3237±601 vs 4293±501 mm/mm3 in controls). It was not statistically different in animals with partial renal ablation+rhEpo+antihypertensive treatment (3620±828 mm/mm3) compared to partial ablation alone.
Conclusion. The study shows that lack of Epo does not cause, or contribute to, the deficit of capillary growth in the hypertrophied left ventricle of rats with renal failure. In addition, a rise in haematocrit is not accompanied by beneficial effects on alterations of cardiovascular structure in experimental renal failure.
Keywords: experimental renal failure; heart; capillarization; rhEpo
Correspondence and offprint requests to: Prof. Dr Kerstin Amann, Department of Pathology, University Erlangen-Nürnberg, Krankenhausstr. 8–10, D-91054 Erlangen, Germany. E-mail:kerstin. amann{at}patho.imed. uni\|[hyphen]\|erlangen. de.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. K. de Bie, B. van Dam, A. Gaasbeek, M. van Buren, L. van Erven, J. J. Bax, M. J. Schalij, T. J. Rabelink, and J. W. Jukema The current status of interventions aiming at reducing sudden cardiac death in dialysis patients Eur. Heart J., July 1, 2009; 30(13): 1559 - 1564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. K. M. Windt, R. H. Henning, A. C. A. Kluppel, Y. Xu, D. de Zeeuw, and R. P. E. van Dokkum Myocardial infarction does not further impair renal damage in 5/6 nephrectomized rats Nephrol. Dial. Transplant., October 1, 2008; 23(10): 3103 - 3110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Herzog, J. W. Strief, A. J. Collins, and D. T. Gilbertson Cause-specific mortality of dialysis patients after coronary revascularization: why don't dialysis patients have better survival after coronary intervention? Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2629 - 2633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. van Albada, G. J. du Marchie Sarvaas, J. Koster, M. C. Houwertjes, R. M. F. Berger, and R. G. Schoemaker Effects of erythropoietin on advanced pulmonary vascular remodelling Eur. Respir. J., January 1, 2008; 31(1): 126 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Herzog Can We Prevent Sudden Cardiac Death in Dialysis Patients? Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 410 - 412. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Amann, C. Wanner, and E. Ritz Cross-Talk between the Kidney and the Cardiovascular System J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2112 - 2119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Sharma, D C Gaze, D Pellerin, R L Mehta, H Gregson, C P Streather, P O Collinson, and S J D Brecker Cardiac structural and functional abnormalities in end stage renal disease patients with elevated cardiac troponin T Heart, June 1, 2006; 92(6): 804 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Van der Meer, E Lipsic, R. Henning, K Boddeus, J van der Velden, A. Voors, D. van Veldhuisen, W. van Gilst, R. Schoemaker, J. Leemans, et al. Heart Failure after Myocardial Infarction--Benefit beyond Hemoglobin from Erythropoietin: Erythropoietin Induces Neovascularization and Improves Cardiac Function in Rats with Heart Failure after Myocardial Infarction J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3449 - 3454. [Full Text] [PDF]
|
|
|
|
 |
|
 P. van der Meer, E. Lipsic, R. H. Henning, K. Boddeus, J. van der Velden, A. A. Voors, D. J. van Veldhuisen, W. H. van Gilst, and R. G. Schoemaker Erythropoietin Induces Neovascularization and Improves Cardiac Function in Rats With Heart Failure After Myocardial Infarction J. Am. Coll. Cardiol., July 5, 2005; 46(1): 125 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Herzog Don't forget the defibrillator in the dialysis unit Nephrol. Dial. Transplant., December 1, 2004; 19(12): 2959 - 2960. [Full Text] [PDF]
|
|
|
|
|
|
C. A. Herzog How to Manage the Renal Patient with Coronary Heart Disease: The Agony and the Ecstasy of Opinion-Based Medicine J. Am. Soc. Nephrol., October 1, 2003; 14(10): 2556 - 2572. [Full Text] [PDF]
|
|
|
|
|
|
C. A. Herzog Dismal long-term survival of dialysis patients after acute myocardial infarction: can we alter the outcome? Nephrol. Dial. Transplant., January 1, 2002; 17(1): 7 - 10. [Full Text] [PDF]
|
|
|
|
|
|
K. Amann and E. Ritz Microvascular disease--the Cinderella of uraemic heart disease Nephrol. Dial. Transplant., October 1, 2000; 15(10): 1493 - 1503. [Abstract] [Full Text] [PDF]
|
|